Keywords: b-ms, licenses, kai, heart, drug, deal, includes
B-MS licenses KAI heart drug in a deal that includes $25M upfront payment
Article | 19 May 2008
Privately-held US biotechnology company KAI Pharmaceuticals will receive a $25.0 million upfront cash payment from drug major Bristol-Myers Squibb as part ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
